← Leaderboards
Omar Abdel-Wahab
Sloan-Kettering Inst Can Research
$18,758,829
Attributed
$33,725,581
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.5M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$44,492,383 · 18
By mechanism
R01$20,062,628 · 6
P50$13,639,440 · 7
UG1$4,452,250 · 1
K12$3,810,556 · 1
R35$1,034,176 · 1
K08$849,420 · 1
Top collaborators
- Robert K Bradley19 shared
- Iannis Aifantis5 shared
- Christopher Y Park5 shared
- Simon N Powell5 shared
- Ross L Levine4 shared
- Dan Landau3 shared
- Eytan Stein3 shared
- Alexander Drilon2 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Benjamin Heath Durham$1,043,325
- Sheng Cai$1,444,218
- Xiang Zhang$12,735,442
- Scott Evan Millman$618,228
- Eytan Stein$0
Others in their field
Top investigators on “Genetic”
- Richard A Gibbs · Baylor College Of Medicine$577,061,667
- Eric S Lander · Whitehead Institute For Biomedical Res$560,806,052
- David R. Weir · University Of Michigan At Ann Arbor$322,225,557
- Richard K. Wilson · Washington University$316,685,275
- Lawrence Corey · Fred Hutchinson Cancer Center$312,182,347
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$302,429,647
Research focus
GeneticMutantMutationLeukemiaCellsSamplingRna SplicingMolecularDysmyelopoietic SyndromesRecurrenceMalignant NeoplasmsProteinsPathogenesisHematopoieticHematopoiesisInsightNovel TherapeuticsClinical TrialsGenesProgramsAcute Myelocytic LeukemiaBaseAffectGenomics
Grant awards (70)
The Memorial Sloan Kettering Cancer Center SPORE in Leukemia$2,350,964
P50 · FY2025 · CA · contact PI
Understanding and Targeting Aberrant RNA Splicing in Leukemia$1,034,176
R35 · FY2025 · CA · contact PI
MSK Paul Calabresi Career Development Award for Clinical Oncology$804,720
K12 · FY2025 · CA
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$799,380
R01 · FY2025 · HL
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia$719,414
R01 · FY2025 · CA
Administrative Core$235,097
P50 · FY2025 · CA · contact PI
Career Enhancement Program$235,096
P50 · FY2025 · CA · contact PI
Project 3: Therapeutic inhibition of splicing through inhibition of protein arginine methylation in leukemia$235,096
P50 · FY2025 · CA · contact PI
Investigational Cancer Therapeutics Training Program (ICTTP)$59,553
T32 · FY2025 · CA
The Memorial Sloan Kettering Cancer Center SPORE in Leukemia$2,256,925
P50 · FY2024 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$848,075
UG1 · FY2024 · CA
MSK Paul Calabresi Career Development Award for Clinical Oncology$720,882
K12 · FY2024 · CA
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia$683,443
R01 · FY2024 · CA
Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkit$667,048
R01 · FY2024 · HL
Interrogating the minor spliceosome to understand and treat leukemia$626,267
R01 · FY2024 · CA · contact PI
Investigational Cancer Therapeutics Training Program (ICTTP)$584,360
T32 · FY2024 · CA
Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia$528,062
R01 · FY2024 · CA · contact PI
Project 3: Therapeutic inhibition of splicing through inhibition of protein arginine methylation in leukemia$374,760
P50 · FY2024 · CA · contact PI
Administrative Core$132,571
P50 · FY2024 · CA · contact PI
Career Enhancement Program$80,396
P50 · FY2024 · CA · contact PI
The Memorial Sloan Kettering Cancer Center SPORE in Leukemia$1,621,553
P50 · FY2023 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$892,711
UG1 · FY2023 · CA
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$791,584
R01 · FY2023 · HL
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia$748,641
R01 · FY2023 · CA
MSK Paul Calabresi Career Development Award for Clinical Oncology$746,534
K12 · FY2023 · CA
Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkit$680,662
R01 · FY2023 · HL
Interrogating the minor spliceosome to understand and treat leukemia$646,044
R01 · FY2023 · CA · contact PI
Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia$544,739
R01 · FY2023 · CA · contact PI
Project 3: Therapeutic inhibition of splicing through inhibition of protein arginine methylation in leukemia$311,223
P50 · FY2023 · CA · contact PI
Administrative Core$69,032
P50 · FY2023 · CA · contact PI
Career Enhancement Program$16,860
P50 · FY2023 · CA · contact PI
The Memorial Sloan Kettering Cancer Center SPORE in Leukemia$2,186,396
P50 · FY2022 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$892,711
UG1 · FY2022 · CA
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$791,584
R01 · FY2022 · HL
MSK Paul Calabresi Career Development Award for Clinical Oncology$769,210
K12 · FY2022 · CA
Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkit$698,037
R01 · FY2022 · HL
Interrogating the minor spliceosome to understand and treat leukemia$646,044
R01 · FY2022 · CA · contact PI
Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia$544,735
R01 · FY2022 · CA · contact PI
Project 3: Therapeutic inhibition of splicing through inhibition of protein arginine methylation in leukemia$367,707
P50 · FY2022 · CA · contact PI
Administrative Core$125,518
P50 · FY2022 · CA · contact PI
Career Enhancement Program$73,343
P50 · FY2022 · CA · contact PI
The Memorial Sloan Kettering Cancer Center SPORE in Leukemia$2,350,964
P50 · FY2021 · CA · contact PI
MSK Paul Calabresi Career Development Award for Clinical Oncology$769,210
K12 · FY2021 · CA
Interrogating the minor spliceosome to understand and treat leukemia$659,229
R01 · FY2021 · CA · contact PI
Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia$555,855
R01 · FY2021 · CA · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$519,636
R01 · FY2021 · HL
Project 3: Therapeutic inhibition of splicing through inhibition of protein arginine methylation in leukemia$384,164
P50 · FY2021 · CA · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$276,769
R01 · FY2021 · HL
Administrative Core$141,975
P50 · FY2021 · CA · contact PI
Career Enhancement Program$89,800
P50 · FY2021 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$859,607
UG1 · FY2020 · CA
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$824,642
R01 · FY2020 · HL
Interrogating the minor spliceosome to understand and treat leukemia$678,479
R01 · FY2020 · CA · contact PI
Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia$575,103
R01 · FY2020 · CA · contact PI
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance$536,090
R01 · FY2020 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$959,146
UG1 · FY2019 · CA · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$622,278
R01 · FY2019 · HL
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance$520,007
R01 · FY2019 · CA · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$628,575
R01 · FY2018 · HL
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance$511,614
R01 · FY2018 · CA · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$634,684
R01 · FY2017 · HL
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance$542,767
R01 · FY2017 · CA · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$644,704
R01 · FY2016 · HL
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance$546,497
R01 · FY2016 · CA · contact PI
Genetic and molecular basis for SRSF2 mutations in myelodysplasia$670,015
R01 · FY2015 · HL
Role of ASXL1 mutations in myeloid malignancies$169,884
K08 · FY2015 · CA · contact PI
Role of ASXL1 mutations in myeloid malignancies$169,884
K08 · FY2014 · CA · contact PI
Role of ASXL1 mutations in myeloid malignancies$169,884
K08 · FY2013 · CA · contact PI
Role of ASXL1 mutations in myeloid malignancies$169,884
K08 · FY2012 · CA · contact PI
Role of ASXL1 mutations in myeloid malignancies$169,884
K08 · FY2011 · CA · contact PI